Acute cardiac care & resuscitation
Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial
Primary result · Primary clinical endpoint: death, myocardial infarction, or ischaemic strokeResult — go to the resultDifference −4 percentage points 90% CI −10 to 3Authors' conclusion
To our knowledge, this is the first randomised trial to compare P2Y12 inhibitor strategies specifically in patients with AMI-CS. Cangrelor achieved effective platelet inhibition more frequently than crushed ticagrelor at the end of primary percutaneous coronary intervention. Non-inferiority of cangrelor versus crushed ticagrelor was not demonstrated for the primary 30-day clinical endpoint. These trial findings can inform future trials of P2Y12 inhibition strategies in patients with AMI-CS.
Study context
- Population
- Patients older than 18 years with acute myocardial infarction complicated by cardiogenic shock (AMI-CS)randomly assigned, 137 [23%] female, no surviving patients lost to 1-year follow-up
- Participants
- 605 participants
- Comparison
- Intravenous cangrelor vs crushed oral ticagrelor
- Cangrelorn = 298
- Ticagrelorn = 307
- Primary endpoint
- Primary clinical endpoint: death, myocardial infarction, or ischaemic stroke
- Follow-up
- 30 days
Methodological details29 hospitals across five European countries, 1:1 ratio, stratified by centre, age, sex, presence or absence of ST-segment elevation, and mechanical ventilation, non-inferiority
- 29 hospitals across five European countries
- 1:1 ratio, stratified by centre, age, sex, presence or absence of ST-segment elevation, and mechanical ventilation
- Non-inferiority
Primary result
As reported in the abstract
Primary clinical endpoint: death, myocardial infarction, or ischaemic stroke
Cangrelorvs ticagrelor
difference −4 percentage points (90% CI −10 to 3); P for non-inferiority = 0.13
Further findings
| Outcome | Cangrelor | Ticagrelor | P value |
|---|---|---|---|
| Primary laboratory endpoint: platelet reactivity index of less than 50% · end of primary percutaneous coronary intervention | 100% of 56 analysed | 22% of 68 analysed | P < 0.0001 |
- Primary laboratory endpoint: platelet reactivity index of less than 50%: analysed in 56 (19%) patients in the cangrelor group and 68 (22%) in the ticagrelor group
Safety
Major bleeding · 30 days
Original publication
Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial. Lancet. Published 7 November 2026. doi:10. 1016/ s0140-6736(26)00976-1
Composed by AI from the published abstract and checked against it. How Briefs are made →